RBC Capital Reiterates Outperform on Abbott Laboratories, Maintains $128 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Shagun Singh has reiterated an Outperform rating on Abbott Laboratories (ABT) and maintained a price target of $128.
February 14, 2024 | 2:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital maintains an Outperform rating on Abbott Laboratories with a $128 price target.
The reiteration of an Outperform rating and a maintained price target by a reputable analyst like Shagun Singh from RBC Capital is likely to instill confidence among investors and could positively influence Abbott Laboratories' stock price in the short term. Analyst ratings, especially from well-regarded financial institutions, can significantly impact investor sentiment and stock prices.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100